Today: 10 June 2026
Browse Category

NYSE:MRK 4 November 2025 - 30 November 2025

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck & Co. shares closed at $104.83 on Nov. 28, near a 52-week high after a surge from the mid-$80s earlier in the month. The rally followed U.S. and European approvals for new Keytruda cancer drug formulations and positive trial results for Winrevair. Merck was a top contributor to the Dow’s late November gains. The stock is up about 8–9% in 2025 including dividends.
30 November 2025
·
Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck closed at $104.83 on November 28, near its 52-week high, after gaining about 22% in November. Trading volume approached 6 million shares, with an after-hours quote at $104.74. Analysts cited strong earnings, dividend growth, and a diversified pipeline beyond Keytruda as key drivers. Merck’s five-year beta stands at 0.32, indicating lower volatility than the broader market.
30 November 2025
·
Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck shares closed at $104.83 on November 28, 2025, near their 52-week high after a 22% surge in the past month. The stock spent much of early autumn in the mid-$80s before jumping above $100 following third-quarter earnings and positive November news. Analysts are split on valuation, with some models showing MRK as fairly priced and others suggesting significant upside.
30 November 2025
··
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck shares closed at $104.83 on November 28, just below the 52-week high of $105.84 set earlier in the week after a Wells Fargo upgrade. The stock is up about 21% over the past month and 8% year-to-date. Scotia Capital and Level Four Advisory Services have trimmed their Merck holdings, according to new filings. Merck continues to warn investors about an unsolicited mini-tender offer from Tutanota LLC at $65 per share.
29 November 2025
·
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck shares closed near $104.5 on Friday, close to a 52-week high, with market cap near $260 billion. Norges Bank disclosed a new $2.86 billion stake, while Groupama, SEB, and Boston Partners trimmed holdings. The stock jumped 21% in the past month, buoyed by new oncology approvals and bullish research. Merck’s trailing 12-month revenue stands at about $64 billion, with net income near $19 billion.
28 November 2025
···
Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck shares closed Wednesday at $105.3, just below their 52-week high of $105.84, after a 0.3% dip. The stock has surged about 40% since late May, fueled by FDA approval of Keytruda and Padcev for bladder cancer and strong Q3 earnings. Trading volume reached nearly 3.9 million shares. Merck’s market cap stands above $260 billion.
26 November 2025
··
Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

The Dow Jones Industrial Average surged 664.18 points, or 1.43%, to 47,112.45 on Tuesday as investors bet the Federal Reserve will cut rates in December. The S&P 500 rose 0.91%, and the Nasdaq gained 0.67%. Softer retail sales, weaker consumer confidence, and a dip in Treasury yields fueled the move. Futures now price in over 80% odds of a December Fed rate cut.
25 November 2025
···
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck shares rose nearly 4% to $104–$105 in early afternoon trading Tuesday, nearing a 52-week high, after the FDA approved Keytruda plus Padcev for certain bladder cancer patients. The rally, boosted by a Wells Fargo upgrade and strong broker commentary, helped drive the Dow more than 400 points higher. Over 11 million Merck shares changed hands by midday.
25 November 2025
··
Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

The Dow Jones Industrial Average rose 202.86 points, or 0.44%, to 46,448.27 on Monday, as investors bet on a December Fed rate cut amid a government data blackout. The Nasdaq jumped 2.69% and the S&P 500 gained 1.55%. Treasury yields slipped to around 4.03%. The Bureau of Labor Statistics canceled the October CPI release due to the federal shutdown.
25 November 2025
·········
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck shares climbed nearly 4% to around $101.40 by early afternoon Monday, nearing 2025 highs after Wells Fargo upgraded the stock to “Overweight” and raised its price target to $125. The move followed new FDA approvals and pipeline updates. Options activity surged, with call volume outpacing puts more than 3:1. Merck’s market cap stood at about $252 billion.
24 November 2025
··
Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck shares jumped about 4% to $101.97 on Monday after Wells Fargo upgraded the stock and raised its price target to $125. The move followed new data on Merck’s hematology pipeline, another FDA approval for Keytruda in bladder cancer, and increased institutional buying. MRK traded at its highest level since January, with technical indicators signaling overbought conditions.
24 November 2025
·
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck urged shareholders to reject Tutanota LLC’s unsolicited mini-tender offer of $65 per share, about 25–32% below recent prices. The company raised its quarterly dividend to $0.85 and reported FDA approval for new Keytruda-based bladder cancer treatments. Merck stock traded near $97.76 Friday, up 2.9%, with a market cap of $243 billion.
22 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Merck shares rose about 3%–4% Tuesday after the company said its drug Winrevair met the main goal in a Phase 2 study for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction. Merck plans to advance the drug to Phase 3 trials. The update follows last week’s $9.2 billion deal to acquire Cidara Therapeutics.
18 November 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck shares rose Wednesday after Phase 3 data showed its oral PCSK9 inhibitor enlicitide cut LDL-C by up to 59.7% and matched placebo for safety. The FDA also cleared Promega’s OncoMate MSI Dx as a companion diagnostic for Keytruda plus Lenvima in advanced endometrial carcinoma. JAMA published peer-reviewed results for enlicitide in HeFH.
12 November 2025
··
Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

The Dow fell 0.5% Monday as UnitedHealth and Merck dropped, while the Nasdaq rose 0.5% on Amazon’s 4% jump after a $38 billion OpenAI deal. Palantir slid 8% despite beating revenue estimates, dragging other AI stocks lower. Wall Street leaders and Michael Burry warned of an AI-driven bubble and possible correction. Investors showed caution as weak manufacturing data and Fed policy jitters reversed early gains.
4 November 2025
·········
1 … 5 6 7 8

Stock Market Today

  • Starbucks Considers Selling Stake or IPO for Japan Unit Valued at $3.1 Billion
    June 10, 2026, 11:25 AM EDT. Starbucks is exploring strategic options for its Japan unit, including a potential sale of a stake or an initial public offering (IPO). The coffee chain has engaged in preliminary discussions with investment banks regarding these possibilities. The Japan unit could be valued at as much as $3.1 billion, reflecting its significant market presence in the region. This move aligns with Starbucks' broader strategy to optimize its global operations and capitalize on strong demand in Asia.

Latest articles

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

10 June 2026
Dow drops 0.55% to 50,592 after May CPI jumps 4.2% year-on-year, matching forecasts but fueled by a 7% surge in gasoline prices and rising energy costs, as renewed U.S.-Iran tensions and sharp losses in AI and industrial stocks add to investor caution, with Super Micro Computer plunging 14.2% on $7 billion equity plans and XPO, J.B. Hunt, Old Dominion falling up to 6.2% after Amazon expands freight service.
S&P 500 Swings After Hot CPI, AI Names Under Pressure

S&P 500 Swings After Hot CPI, AI Names Under Pressure

10 June 2026
May inflation jumped 4.2%—the fastest pace since April 2023—matching forecasts but keeping the Fed on hold, as energy prices fueled the rise; S&P 500 and Nasdaq steadied after early losses, but AI-linked stocks slid, with Super Micro Computer tumbling on a $7 billion share sale plan that risks diluting investors.
Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Go toTop